metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus dacarbazine
	nivolumab alone
	CheckMate 066, 2015 N Engl J Med 2015;372:320-30 JAMA Oncol 2019; 5:187-194 Ann. Oncol. 2016; 27:1940-6 NCT01721772	RCT	mML - L1 - BRAF wild	nivolumab	dacarbazine	previously untreated patients who had unresectable metastatic melanoma without a BRAF mutation (stage III or IV).	210 / 208	low	conclusif	demonstrated 58 % decrease in deaths (OS) (PE) demonstrated 57 % decrease in progression or deaths (PFS) (PE) suggested 54 % decrease in deaths (OS) (extension) suggested 58 % decrease in PFS (extension) more...
versus pembrolizumab alone
	atezolizumab plus cometinib
	IMspire-170, 2020 Ann Oncol 2020 Dec 10;S0923-7534(20)43203-X. NCT03273153	RCT	mML - L1 - BRAF wild	cometinib plus atezolizumab	pembrolizumab	patient with confirmed locally advanced and unresectable or metastatic melanoma that was negative for BRAFV600 mutations with no prior systemic treatment for advanced melanoma.	222 / 224	some concern	inconclusive	inconclusive 15 % increase in progression or deaths (PFS) (PE)